List Results  
  Refine Search  
  Results by Topic  
  Results on Map  
  Search Details  
Found 32 studies with search of:   Belarus
Hide studies that are not seeking new volunteers.
  Display Options
Rank Status Study
1 Recruiting Study of LJP 394 in Lupus Patients With History of Renal Disease
Conditions: Lupus Erythematosus, Systemic;   Lupus Nephritis
Interventions: Drug: abetimus sodium (LJP 394) and/or placebo solution;   Drug: abetimus sodium (LJP 394);   Drug: Phosphate-buffered saline
2 Enrolling by invitation Long-Term Extension Study of the SERAPHIN Study, to Assess the Safety and Tolerability of ACT 064992 in Patients With Symptomatic Pulmonary Arterial Hypertension
Condition: Pulmonary Arterial Hypertension
Intervention: Drug: ACT-064992
3 Recruiting LUME-Lung 1: BIBF 1120 Plus Docetaxel as Compared to Placebo Plus Docetaxel in 2nd Line Non-Small Cell Lung Cancer (NSCLC)
Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: BIBF 1120;   Drug: placebo;   Drug: docetaxel
4 Completed A Double Blind Study for the Treatment of Acute Ulcerative Colitis
Condition: Ulcerative Colitis
Intervention: Drug: Mesalamine
5 Recruiting Study of ACT-064992 on Morbidity and Mortality in Patients With Symptomatic Pulmonary Arterial Hypertension
Condition: Pulmonary Arterial Hypertension
Interventions: Drug: ACT-064992;   Drug: ACT-064992;   Drug: Placebo
6 Recruiting Study to Test the Efficacy and Safety of the Beta-3 Agonist YM178 in Subjects With Symptoms of Overactive Bladder
Condition: Urinary Bladder, Overactive
Interventions: Drug: YM178;   Drug: Tolterodine 4 mg;   Drug: Placebo
7 Recruiting Efficacy and Safety of Oral BG00012 in Relapsing-Remitting Multiple Sclerosis
Condition: Relapsing-Remitting Multiple Sclerosis
Intervention: Drug: BG00012
8 Recruiting Treatment Effect of Saxagliptin Compared With Placebo in Patients With Type 2 Diabetes and Renal Impairment
Condition: Type 2 Diabetes
Interventions: Drug: Saxagliptin;   Drug: Placebo
9 Recruiting Efficacy and Safety Study of Oral BG00012 With Active Reference in Relapsing-Remitting Multiple Sclerosis
Condition: Relapsing-Remitting Multiple Sclerosis
Intervention: Drug: BG00012
10 Active, not recruiting Cetrorelix Pamoate in Patients With Symptomatic Benign Prostatic Hypertrophy (BPH)
Condition: Benign Prostatic Hypertrophy
Interventions: Drug: cetrorelix;   Drug: cetrorelix;   Drug: placebo
11 Recruiting Study to Test the Long Term Safety and Efficacy of the Beta-3 Agonist YM178 in Patients With Symptoms of Overactive Bladder
Condition: Urinary Bladder, Overactive
Interventions: Drug: YM178;   Drug: Tolterodine 4 ng
12 Active, not recruiting "REDUCE" - A Clinical Research Study To Reduce The Incidence Of Prostate Cancer In Men Who Are At Increased Risk
Condition: Prostate Cancer
Intervention: Drug: Dutasteride
13 Active, not recruiting A Phase III A Study to Assess the Safety of CDP870 for up to 30 Months Exposure
Condition: Crohn's Disease
Intervention: Biological: CDP870
14 Recruiting A Study of Galiximab + Rituximab Versus Rituximab + Placebo in Follicular Non-Hodgkin's Lymphoma (NHL)
Condition: Lymphoma, Non-Hodgkin's
Interventions: Drug: Galiximab in combination with rituximab;   Drug: Rituximab in combination with placebo
15 Enrolling by invitation Retreatment Study of Galiximab + Rituximab in Follicular Non-Hodgkin's Lymphoma (NHL)
Condition: Non-Hodgkin Lymphoma
Intervention: Drug: galiximab in combination with rituximab
16 Recruiting A Study to Compare MPR With MP in Newly Diagnosed Multiple Myeloma Subjects 65 Years Old or Older
Condition: Newly Diagnosed Multiple Myeloma
Intervention: Drug: Lenalidomide
17 Completed Livial Intervention Following Breast Cancer; Efficacy, Recurrence and Tolerability Endpoints (LIBERATE)
Conditions: Breast Cancer;   Climacteric Symptoms
Interventions: Drug: tibolone 2.5 mg/day;   Drug: placebo
18 Not yet recruiting Genes Causing Ebstein's Anomaly
Conditions: Heart Septal Defects, Ventricle;   Heart Defects, Congenital;   Double Outlet Right Ventricle;   Truncus Arteriosus, Persistent
Intervention:
19 Active, not recruiting Study to Assess the Safety of CDP870 for up to 30 Months Following Reintroduction of Treatment
Condition: Crohn's Disease
Intervention: Biological: CDP870
20 Active, not recruiting Scientific Protocol for the Study of Thyroid Cancer and Other Thyroid Disease in Belarus Following the Chernobyl Accident
Conditions: Thyroid Cancer;   Thyroid Disease
Intervention:

Previous Page Studies Shown (1-20) Next (21-32)
  RSS Feed for studies found by your search that were received in the last 14 days
  Download Options




U.S. National Library of Medicine,  Contact Help Desk
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services